amgen

Do we wait it out for OX40? Or is it time to jump ship now

Amgens CDNA team has to be the worst people i've worked for. The environment they fostered is not one of actual progression. Its who can talk the loudest, and kiss the ring of Anthony. People who like to talk and yap it up are favored, but if you're one to just lay low, you have a target...

Anybody worked for both abbvie and Amgen? thoughts on which is the better company to sell for and work for?

Amgen BD looking to salvage the revenue being lost from its EPO business. Both Vifor and Davita (converting fast from Epogen to Mircera) are using Roche product. Its best and the only option is Vafseo, which also has better labeling than GSK oral product, and also touts existing partnership with...

1000 people all together and a bunch of drunks. Amgen Golden days are behind them!

Apart from the 350 from Horizon, Amgen hasnt announced any other lay offs, nevertheless i found from my old friends at ATO and AML that departments are being erased…why there is NOTHING in the news, firing happened in the last 2 weeks…WTF

Anyone have any insight on the new associate director pay range ?

BCBU just got lunch budgets. Anyone else?

Bristol-Myers-Squibb announced that Amgen will acquire Celgene’s Otezla business for $13.4 billion in a cash transaction. Bristol-Myers now expects to complete the pending merger with Celgene by the end of 2019. For More:

Hi Everyone, Currently in the process of interviewing for a ED role based out of TO. So far the opportunity seems intriguing. While I have had some engagement with the Talent Acquisition/Exec Recruiting team, they have been somewhat vague about the compensation structure, limited to...

Amgen earnings coverage With the recent launch of new products, sales improved 4% to $6.05 billion while profits jumped 17% touching $3.83 per share due to strong product sales. Free cash flow for the quarter came in at $1.9 billion, down 9.5% compared to last year due to increased tax outgo...

Amgen (AMGN) announced positive top-line results from the phase 3 trial of its biosimilar candidate ABP 710. The drug is a biosimilar of Johnson & Johnson’s blockbuster rheumatoid arthritis drug, Remicade (infliximab). If the drug succeeds, Amgen is well positioned to be a key player in the...

Mylan gets FDA approval for its first biosimilar infection-fighting treatment Neulasta manufactured by Amgen. Mylan plans for the first launch of its biosim Fulphila in a few weeks, with an aim of offering an inexpensive treatment for cancer patients...

Amgen reported an increase in first quarter earnings, driven by broad-based growth in product sales. Both earnings and sales topped street estimates. Earnings rose 16% year-over-year to $3.25 per share during the quarter. Besides higher product sales, the growth was also driven by a decline in...

$AMGN Amgen reported a loss in the fourth quarter of 2017 due to the inclusion of a $6.1 billion charge related to the impacts of the U.S. corporate tax reform. The results came in below analysts expectations. In addition, the company issued guidance for the year 2018, which remained in line...

This is the second patent win for Sandoz in December 2017. Allergan is expected to file for rehearing within 30 days on patent ruling. Earlier in Dec., Sandoz also won a patent case against Amgen.

http://alph.st/bf3c0558 Lilly joins the migraine drug race with Novartis and Amgen, as FDA accepts to review Lilly's Galcanezumab. Already, Teva filed a lawsuit in October 2017, seeking to block Lilly's migraine drug to market in the U.S. The size of the migraine market is expected to more than...

https://alphastreet.com/bite/d578727 Amgen, that is in the process of refreshing its product portfolio, reported higher-than-expected 3Q profit, but sales declined in some of its biggest established products.

https://alphastreet.com/bite/d578727 Amgen, that is in the process of refreshing their product portfolios, reported higher-than-expected 3Q profit, but sales declined in some of its biggest established products.

FDA approves Allergan and Amgen's biosimilar of Roche's Avastin.